The proposed Marinus Link electricity interconnector will bring massive wins for the state, including preserving our climate credentials over the long term, a committee heard. Here’s why.

Cantor Fitzgerald analyst Charles Duncan lowered the firm’s price target on Marinus Pharmaceuticals (MRNS) to $4 from $13 and keeps an Overweight rating on the shares. The company’s Phase III ...

Fintel reports that on October 25, 2024, Jefferies downgraded their outlook for Marinus Pharmaceuticals (LSE:0JYL) from Buy to Hold. There are 193 funds or institutions reporting positions in ...

On Thursday, Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) stock plunged after the company revealed disappointing data from the Phase 3 TrustTSC trial of oral ganaxolone for seizures associated with ...

« On agenda for Monday’s Burien City Council meeting: public hearing on budget, code amendments, minimum wage & more Free Fall concert by Kennedy Catholic Jazz Band and Orchestra is Tuesday ...

The trial demonstrated a median reduction in EEG seizure burden Credit: Ground Picture/Shutterstock. Marinus Pharmaceuticals has reported results from the pivotal Phase III RAISE trial for intravenous ...

RADNOR, Pa. - Marinus (NASDAQ:MRNS) Pharmaceuticals, Inc. (NASDAQ:MRNS) shared new findings from its Phase 3 RAISE trial on intravenous (IV) ganaxolone, revealing promising results for treating ...

RADNOR, Pa.--(BUSINESS WIRE)--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today ...

RADNOR, Pa., October 15, 2024--(BUSINESS WIRE)--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...